BRL 35135

Drug Profile

BRL 35135

Latest Information Update: 28 Sep 1998

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Mochida Pharmaceutical
  • Class Acetic acids; Antihyperglycaemics; Phenethylamines
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 28 Sep 1998 Discontinued-Clinical for Type-2 diabetes mellitus in United Kingdom (PO)
  • 28 Sep 1998 Discontinued-Preclinical for Type-2 diabetes mellitus in Japan (PO)
  • 28 Sep 1998 Discontinued-Preclinical for Diabetes mellitus in Finland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top